- Entres Pubmed
- Pubmed Research Papers
- MEDLINE/PubMed Data
- MEDLINE/PubMed Baseline
- MEDLINE/PubMed XML
- Pubmed Journals
- NCBI Pubmed
- Medline Search
- Pubmed Citation
- Medline Articles
- MESH Terminology
MEDLINE PubMed Journal Citation Database
This dataset contains NLM’s database of citations and abstracts in the fields of medicine, nursing, dentistry, veterinary medicine, health care systems, and preclinical sciences.
Get The Data
- ResearchNon-Commercial, Share-Alike, Attribution Free Forever
- CommercialCommercial Use, Remix & Adapt, White Label Log in to download
MEDLINE is the U.S. National Library of Medicine® (NLM) premier bibliographic database that contains more than 23 million references to journal articles in life sciences with a concentration on biomedicine. A distinctive feature of MEDLINE is that the records are indexed with NLM Medical Subject Headings (MeSH®)
The subject scope of MEDLINE is biomedicine and health, broadly defined to encompass those areas of the life sciences, behavioral sciences, chemical sciences, and bioengineering needed by health professionals and others engaged in basic research and clinical care, public health, health policy development, or related educational activities. MEDLINE also covers life sciences vital to biomedical practitioners, researchers, and educators, including aspects of biology, environmental science, marine biology, plant and animal science as well as biophysics and chemistry. Publishers submit journals to an NIH-chartered advisory committee, the Literature Selection Technical Review Committee (LSTRC), which reviews and recommends journals for MEDLINE. The LSTRC considers the quality of the scientific content of a journal, including originality and the importance of the content for the MEDLINE global audience, using the guidelines found on the NLM Fact Sheet MEDLINE Journal Selection.
MEDLINE is the primary component of PubMed®, part of the Entrez series of databases provided by the NLM National Center for Biotechnology Information (NCBI). In addition to MEDLINE citations, PubMed also contains:
– In-process citations that provide a record for an article before it is indexed with MeSH® and added to MEDLINE or converted to out-of-scope status.
– Citations that precede the date that a journal was selected for MEDLINE indexing.
– Some OLDMEDLINE citations that have not yet been updated with current vocabulary and converted to MEDLINE status.
– Citations to articles that are out-of-scope (e.g., covering plate tectonics or astrophysics) from certain MEDLINE journals, primarily general science and general chemistry journals, for which the life sciences articles are indexed with MeSH for MEDLINE.
– Citations to some additional life science journals that submit full-text articles to PMC® (PubMed Central®) and receive a qualitative review by NLM.
– Citations for the majority of books and book chapters available on the NCBI Bookshelf.
MedlineCitation Status attribute
Records submitted to NLM electronically by publishers are added to PubMed at NLM and given in In-Data-Review status. Records in this status have undergone review at the journal issue level; i.e., the journal title, date of publication and volume/issue elements (referred to as the source data) are checked. They are not yet MEDLINE records because they have not undergone complete quality review and MeSH indexing; thus they should not be identified as MEDLINE records.
Records in this status have undergone a citation level review; i.e., the author names, article title, and pagination are checked. All In-Data-Review records that entered the workflow via publisher electronic submission are redistributed again in In-Process status whether or not they were revised as a result of the second citation level review, and are not identified in any way as having been revised or not having been revised. Records created via NLM current other data entry mechanism, scanning/optical character recognition (OCR), are distributed for the first time in In-Process status after their creation. They are not yet MEDLINE records because they have not undergone complete quality review and MeSH indexing; thus they should not be identified as MEDLINE records. Most in-process records are eventually indexed with MeSH Headings and are elevated to completed MEDLINE status. However, some are determined to be out of scope (e.g., articles on plate tectonics or astrophysics from certain MEDLINE journals, primarily general science and chemistry journals, for which the life sciences articles are indexed for MEDLINE) and are not elevated to MEDLINE status; instead they become PubMed-not-Medline final status records. In rare cases the records are deleted and do not become PubMed-not-MEDLINE records.
In-process records undergo rigorous quality assurance routines before they are elevated to MEDLINE status or to PubMed-not-MEDLINE status. Records in MEDLINE status are the only ‘true’ MEDLINE records .
A small percentage of the records in the OLDMEDLINE subset are in MedlineCitation Status = OLDMEDLINE. The criterion for records to be in OLDMEDLINE status is that all the original MeSH Headings have not yet been mapped to current MeSH. NLM exports both new and revised OLDMEDLINE records on an irregular and infrequent basis.
Records in this status are from journals included in MEDLINE and have undergone quality review but are not assigned MeSH headings because the cited item is not in scope for MEDLINE either by topic or by date of publication, or from non-MEDLINE journals and have undergone quality review.
Records in Publisher status are not distributed via bulk download. At this time approximately 98% of PubMed’s content is distributed via bulk download. At any given time, there are between 400,000 to 500,000 additional records in Publisher MedlineCitation Status in PubMed. These are citations to author manuscripts of articles published by NIH-funded researchers and citations to books in the NCBI Bookshelf etc.
The values and their definitions for Citation Subset are as follows. Note that several are closed subsets no longer being assigned.
AIM = citations from Abridged Index Medicus journals, a list of about 120 core clinical, English language journals.
B = citations from non-Index Medicus journals in the field of biotechnology (not currently used).
C = citations from non-Index Medicus journals in the field of communication disorders (not currently used).
D = citations from dental journals.
E = citations in the field of bioethics (includes records from the former BIOETHICS database).
F = older citations from one journal prior to its selection for Index Medicus; used to augment the database for NLM International MEDLARS Centers (not currently used).
H = citations from non-Index Medicus journals in the field of health administration (includes records from the former HealthSTAR database).
IM = citations from Index Medicus journals.
J = citations in the field of population information (not currently used; on records from the former POPLINE® database).
K = citations from non-Index Medicus journals relating to consumer health.
N = citations from nursing journals.
OM = pre-1966 citations from the older print indices of the Cumulated Index Medicus (CIM) and the Current List of Medical Literature (CLML).
Q = citations in the field of the history of medicine (includes records from the former HISTLINE® database).
QIS = citations from non-Index Medicus journals in the field of the history of medicine. (For NLM use effective in late 2006 because they require special handling at NLM; not a subset of Q; some journals previously designated as Q are now QIS.)
QO is subset of Q – indicates older history of medicine journal citations that were created before the former HISTLINE file was converted to a MEDLINE-like format. (For NLM use because they require special handling at NLM.)
R = citations from non-Index Medicus journals in the field of population and reproduction (not currently used).
S = citations in the field of space life sciences (includes records from the former SPACELINE™ database).
T = citations from non-Index Medicus journals in the field of health technology assessment (includes records from the former HealthSTAR database).
X = citations in the field of AIDS/HIV (includes records from the former AIDSLINE® database).
About this Dataset
1946 to 2018
John Snow Labs; National Library of Medicine (NLM);
|Source License URL|
|Source License Requirements||
Pubmed Journals, NCBI Pubmed, Medline Search, Pubmed Citation, Medline Articles, MESH Terminology
Entres Pubmed, Pubmed Research Papers, MEDLINE/PubMed Data, MEDLINE/PubMed Baseline, MEDLINE/PubMed XML
|PubMed_ID||The PubMed unique identifier, is a 1 to 8-digit accession number with no leading zeros.||integer||required : 1level : Nominal|
|PubMed_Version||Used to accommodate the model of publishing known as "versioning"||integer||required : 1level : Interval|
|Citation_Status||Indicates the stage of a citation.||string||required : 1enum : Array (  => In-Process  => PubMed-not-MEDLINE  => In-Data-Review  => Publisher  => MEDLINE  => OLDMEDLINE )|
|Citation_Owner||Indicates the The party responsible for creating and validating the citation. Each citation has only one MedlineCitation Owner||string||required : 1enum : Array (  => NLM  => NASA  => PIP  => KIE  => HSR  => HMD  => SIS  => NOTNLM )|
|Citation_VersionID||Used with “versioned” citations||string||-|
|Citation_Version_Date||Used with “versioned” citations||date||-|
|Citation_Indexing_Method||Indexing method used for citation||string||-|
|Citation_Record_Completed_Date||Date processing of the record ends i.e., MeSH Headings have been added, quality assurance validations are completed, and the completed record subsequently is distributed to PubMed.||date||-|
|Citation_Record_Revised_Date||May reside on records with Status = MEDLINE, OLDMEDLINE, and PubMed-not-MEDLINE. It identifies the date a change is made to a record in one of those statuses, either as a result of individual or global maintenance.||date||-|
|Citation_Other_SourceID||identifies a.) the organization responsible for the information on the citation or the document where the information originated, and b.) a unique number for that citation or document.||string||-|
|Citation_Other_Abstract_Text||Indicates the abstract created by a collaborating partner or other entity||string||-|
|Citation_Other_Abstract_Text_Type||Type of Other Abstract||string||-|
|Citation_Other_Abstract_Text_Language||Indicate on behalf of publishers that there are additional abstracts available at the publishers' Web sites or elsewhere.||string||-|
|Citation_Other_Abstract_Text_Copyright_Info||Indicate copyright statement provided by the publisher of the journal||string||-|
|Citation_Mesh_Headings_List||NLM controlled vocabulary, Medical Subject Headings (MeSH®), is used to characterize the content of the articles represented by MEDLINE citations||string||-|
|Citation_Chemical_Drug_List||Contains one or more chemicals or drugs,which are displayed as registry number and name of substance.||string||-|
|Citation_Protocol_Disease_List||Indicates Protocol Class 2 Supplementary Concept Record (SCR) terms and Disease Class 3 SCR terms||string||-|
|Citation_Keywords_List||Contains controlled terms that describe the content of the article.||string||-|
|Citation_Number_Of_References||Contains the number of bibliographic references listed in the article.||integer||level : Ratio|
|Citation_Subset||identifies the subset for which MEDLINE records from certain journal lists or records on specialized topics were created. Some of these values are found on extremely small numbers of records.||string||-|
|Citation_Comments_Corrections||These data pertain to and contain citations to associated journal publications, e.g., comments, errata, retractions, or cited references, and enable outside links between the record at hand to its associated citation(s).||string||-|
|Citation_Gene_Symbol_List||Contains the "symbol" or abbreviated form of gene names as reported in the literature.||string||-|
|Citation_Personal_Name_Subject_List||Used for citations that contain a biographical note or obituary, or are entirely about the life or work of an individual or individuals.||string||-|
|Citation_Space_Flight_Mission||Contains the space flight mission name and/or number when results of research conducted in space are covered in a publication.||string||-|
|Citation_Investigator_List||Contain personal names of individuals (e.g., collaborators and investigators) who are not authors of a paper but rather are listed in the paper as members of a collective/corporate group that is an author of the paper.||string||-|
|Citation_General_Note||Contains supplemental or descriptive information related to the document cited in the MEDLINE record. It is a 'catchall' for various types of information included by NLM collaborating producers or by NLM.||string||-|
|Citation_Conflict_Of_Interest_Statement||Conflict of interest statement||string||-|
|Journal_ISSN||ISSN (International Standard Serial Number) is always an eight-character value that uniquely identifies the cited journal. It is nine characters long in the hyphenated form: XXXX-XXXX.||string||-|
|Journal_ISSN_Type||Indicates which of the ISSNs assigned to the journal is recorded in the citation.||string||enum : Array (  => Electronic  => Print  => Undetermined )|
|Journal_Title||The full journal title||string||required : 1|
|Journal_Title_ISO_Abbreviation||ISO Abbreviations are constructed at NLM to assist NCBI in linking from GenBank to PubMed. ISO Abbreviations created after 2007 are identical to the NLM title abbreviations.||string||-|
|Journal_Cited_Medium||Indicates whether a citation is processed/indexed at NLM from the online or the print version of the journal.||string||enum : Array (  => Internet  => Print )|
|Journal_Volume_Issue||The volume number and the issue (part or supplement) of the journal in which the article was published.||string||-|
|Journal_Published_Date||Contains the full date on which the issue of the journal was published||string||-|
|Journal_Published_Country||Contains the place of publication of the journal.||string||-|
|Journal_Title_Standard_Abbreviation||Contains the standard abbreviation for the title of the journal in which an article appeared.||string||-|
|Journal_NLM_ID||It may appear as seven, eight or nine charcaters and is the preferred element to use when looking for the serial record for the journal in which the article was published.||string||required : 1|
|Journal_ISSN_Linking||Contains the ISSN designated by the ISSN Network to enable co-location or linking among the different media versions of a continuing resource||string||-|
|Article_Title||Contains the entire title of the journal article.It is always in English; those titles originally published in a non-English language and translated are enclosed in square brackets.||string||-|
|Article_Authors||Contains the Personal and collective (corporate) author names published with the article.It includes author's lastname, forename, suffix, collective (corporate) names and affliation information||string||-|
|Article_Language||Contains the The language in which an article was published.||string||required : 1|
|Article_Publish_Model||Identify the medium/media in which the cited article is published.||string||required : 1enum : Array (  => Print  => Print-Electronic  => Electronic  => Electronic-Print  => Electronic-eCollection )|
|Article_Abstract_Text||English-language abstracts taken directly from the published article. Abstracts in records may be truncated.||string||-|
|Article_Abstract_Text_Copyright_Info||Contains a copyright statement provided by the publisher of the journal and appears only on records supplied electronically to NLM by the publisher.||string||-|
|Article_Publication_Types||It identifies the type of article indexed for MEDLINE; it characterizes the nature of the information or the manner in which it is conveyed as well as the type of research support received (e.g., Review, Letter, Retracted Publication, Clinical Conference, Research Support, N.I.H., Extramural).||string||-|
|Article_Pagination||Indicates the inclusive pages for the article cited.||string||-|
|Article_ELocationID||Provides an electronic location for items which lack standard page numbers. The element houses Digital Object Identifiers (DOIs) or Publisher Item Identifiers (PIIs) that are provided by publishers for new citations submitted to NLM for inclusion in MEDLINE/PubMed.||string||-|
|Article_DataBank_List||Contains information pertaining to the registration of several types of data: 1) molecular sequence data; 2) clinical trial numbers; 3) gene expression/molecular abundance data; 4) PubChem identifiers; 5)Two general research databanks, the Dryad Digital Repository and figshare; and 6) BioProject identifiers.||string||-|
|Article_Grant_List||Contains following information 1) research grant or contract number 2) grant acronym 3) institute acronym followed by the agency's hierarchical structure from lower to higher entity or agency name 4) country of the granting agency||string||-|
|Article_Vernacular_Title||Used for articles published in non-English languages and contains the original, untranslated title.||string||-|
|Article_Electronic_Published_Date||Contains the date the publisher made an electronic version of the article||date||-|
|PubMed_History||Changes in the pubmed records, along with the status and the dates when it was changed||string||-|
|PubMed_Publication_Status||Publication status of the record||string||-|
|PubMed_ArticleID_List||List of article ids and types||string||-|
|PubMed ID||PubMed Version||Citation Status||Citation Owner||Citation VersionID||Citation Version Date||Citation Indexing Method||Citation Record Completed Date||Citation Record Revised Date||Citation Other SourceID||Citation Other Abstract Text||Citation Other Abstract Text Type||Citation Other Abstract Text Language||Citation Other Abstract Text Copyright Info||Citation Mesh Headings List||Citation Chemical Drug List||Citation Protocol Disease List||Citation Keywords List||Citation Number Of References||Citation Subset||Citation Comments Corrections||Citation Gene Symbol List||Citation Personal Name Subject List||Citation Space Flight Mission||Citation Investigator List||Citation General Note||Citation Conflict Of Interest Statement||Journal ISSN||Journal ISSN Type||Journal Title||Journal Title ISO Abbreviation||Journal Cited Medium||Journal Volume Issue||Journal Published Date||Journal Published Country||Journal Title Standard Abbreviation||Journal NLM ID||Journal ISSN Linking||Article Title||Article Authors||Article Language||Article Publish Model||Article Abstract Text||Article Abstract Text Copyright Info||Article Publication Types||Article Pagination||Article ELocationID||Article DataBank List||Article Grant List||Article Vernacular Title||Article Electronic Published Date||PubMed History||PubMed Publication Status||PubMed ArticleID List|
|30913102||1||MEDLINE||NLM||Curated||2020-09-08||2022-10-05||D000328 Adult;MajorTopic D001011 Aorta;D021721 Balloon Occlusion;MajorTopic Q000379 methods;D002648 Child;D057510 Endovascular Procedures;Q000295 instrumentation;MajorTopic Q000379 methods;D005260 Female;D006801 Humans;MajorTopic D057446 Hydrodynamics;MajorTopic D008953 Models, Anatomic;D010372 Pediatrics;Q000295 instrumentation;Q000379 methods;D014057 Tomography, X-Ray Computed||IM||1538-943X||Electronic||ASAIO journal (American Society for Artificial Internal Organs : 1992)||ASAIO J||Internet||66;1||2020-01||United States||ASAIO J||9204109||1058-2916||Morphometric and Physiologic Modeling Study for Endovascular Occlusion in Pediatric Trauma Patients.||Carrillo Louis From the Department of Pediatric Surgery, McGovern Medical School, The University of Texas Health Science Center, Houston, Texas.;Skibber Max From the Department of Pediatric Surgery, McGovern Medical School, The University of Texas Health Science Center, Houston, Texas.;Kumar Akshita From the Department of Pediatric Surgery, McGovern Medical School, The University of Texas Health Science Center, Houston, Texas.;George Mitchell From the Department of Pediatric Surgery, McGovern Medical School, The University of Texas Health Science Center, Houston, Texas.;Aziz Shahroz Department of Radiology, McGovern Medical School, The University of Texas Health Science Center, Houston, Texas.;T Harting Matthew From the Department of Pediatric Surgery, McGovern Medical School, The University of Texas Health Science Center, Houston, Texas.;Moore Laura J Texas Trauma Institute, The University of Texas Health Science Center, Houston, Texas.;Cox Charles S Jr From the Department of Pediatric Surgery, McGovern Medical School, The University of Texas Health Science Center, Houston, Texas.||eng||The use of the resuscitative endovascular balloon occlusion of the aorta (REBOA) device is expanding in adult trauma. Reports of its use in pediatric patients have been published, but no guidelines currently exist nor has it been Food and Drug Administration approved in pediatrics. This project develops a model to determine appropriate balloon inflation volumes in pediatric patients to guide potential use. Artificial aortas were three-dimensional (3D) printed using synthetic polymers. Segments were created based on aortic diameters from 289 pediatric trauma patients' computer tomography (CT) scans. These aortic segments were inserted into a circulatory system model featuring two branches to simulate abdominal and upper body perfusion (cerebral, cardiac, and upper extremities). Sonographic flow meters and pressure transducers were placed along the circuit, and measurements were recorded as a REBOA device was inflated in the aortic segment. A negative sigmoidal relationship was observed between device inflation and aortic flow occlusion, with the initial 50% of inflation causing a 10% reduction in flow, followed by a steep decline. With increasing inflation, distal aortic flow and pressure were found to have an inverse relationship with the upper body branch metrics. In conclusion, pediatric patients present with a range of vessel diameters that occlude at various REBOA balloon inflation volumes. This study provides a basis to establish initial inflation volumes for safe REBOA deployment in appropriate pediatric trauma patients.||D016428 Journal Article;D052061 Research Support, N.I.H., Extramural||97-104||doi 10.1097/MAT.0000000000000961||T32 GM008792 GM NIGMS NIH HHS United States||pubmed 2019-3-27 6:0;medline 2020-9-9 6:0;entrez 2019-3-27 6:0||ppublish||pubmed 30913102;doi 10.1097/MAT.0000000000000961;pmc PMC6856426;mid NIHMS1055902;pii 00002480-202001000-00016|
|30913103||1||MEDLINE||NLM||Curated||2020-09-08||2022-10-05||D000368 Aged;MajorTopic D002496 Central Venous Pressure;Q000502 physiology;D015331 Cohort Studies;MajorTopic D017097 Electric Impedance;D005260 Female;D006333 Heart Failure;Q000628 therapy;D006352 Heart Ventricles;Q000503 physiopathology;MajorTopic D006353 Heart-Assist Devices;D006439 Hemodynamics;Q000502 physiology;D006801 Humans;D008297 Male;MajorTopic D055641 Mathematical Concepts;D008875 Middle Aged;MajorTopic D010138 Pacemaker, Artificial||IM||1538-943X||Electronic||ASAIO journal (American Society for Artificial Internal Organs : 1992)||ASAIO J||Internet||66;1||2020-01||United States||ASAIO J||9204109||1058-2916||Estimation of Central Venous Pressure by Pacemaker Lead Impedances in Left Ventricular Assist Device Patients.||Imamura Teruhiko From the Department of Medicine, University of Chicago Medical Center, Chicago, Illinois.;Moss Joshua D From the Department of Medicine, University of Chicago Medical Center, Chicago, Illinois.;Flatley Erin From the Department of Medicine, University of Chicago Medical Center, Chicago, Illinois.;Rodgers Daniel From the Department of Medicine, University of Chicago Medical Center, Chicago, Illinois.;Kim Gene From the Department of Medicine, University of Chicago Medical Center, Chicago, Illinois.;Raikhelkar Jayant From the Department of Medicine, University of Chicago Medical Center, Chicago, Illinois.;Sarswat Nitasha From the Department of Medicine, University of Chicago Medical Center, Chicago, Illinois.;Kalantari Sara From the Department of Medicine, University of Chicago Medical Center, Chicago, Illinois.;Nguyen Ann From the Department of Medicine, University of Chicago Medical Center, Chicago, Illinois.;Juricek Colleen Department of Surgery, University of Chicago Medical Center, Chicago, Illinois.;Burkhoff Daniel Columbia University Medical Center, and Cardiovascular Research Foundation, New York, New York.;Song Tae Department of Surgery, University of Chicago Medical Center, Chicago, Illinois.;Ota Takeyoshi Department of Surgery, University of Chicago Medical Center, Chicago, Illinois.;Jeevanandam Valluvan Department of Surgery, University of Chicago Medical Center, Chicago, Illinois.;Sayer Gabriel From the Department of Medicine, University of Chicago Medical Center, Chicago, Illinois.;Uriel Nir From the Department of Medicine, University of Chicago Medical Center, Chicago, Illinois.||eng||Volume status assessment in left ventricular assist device (LVAD) patients remains challenging. Cardiac resynchronization therapy (CRT) devices are common in LVAD patients, and the impedance across the CRT leads may be associated with hemodynamics and serve as a tool for noninvasive estimation of volume status. Ninety-one sets of measurements including cardiac filling pressures and lead impedances were prospectively obtained during ramp tests from 11 LVAD patients (65.5 Â± 9.7 years old; nine male) with CRT devices. Right atrial (RA), right ventricular (RV), and left ventricular (LV) lead impedances were all significantly associated with central venous pressure (CVP) (p < 0.05). We derived the following equation: estimated CVP = 47.90-(0.086 Ã RA lead impedance) + (0.013 Ã RV lead impedance)-(0.020 Ã LV lead impedance). The estimated CVP had a significant correlation (r = 0.795) and good agreement with the measured CVP (mean difference -0.14 Â± 1.77 mmHg). Applying the above equation on the validation cohort of twenty-one patients also maintained a strong association with measured CVP (r = 0.705). In conclusion, we have derived a novel equation to estimate CVP using lead impedance measurements. This finding may allow noninvasive monitoring of volume status in LVAD patients.||D016428 Journal Article;D052061 Research Support, N.I.H., Extramural;D013485 Research Support, Non-U.S. Gov't||49-54||doi 10.1097/MAT.0000000000000966||T32 HL007381 HL NHLBI NIH HHS United States||pubmed 2019-3-27 6:0;medline 2020-9-9 6:0;entrez 2019-3-27 6:0||ppublish||pubmed 30913103;doi 10.1097/MAT.0000000000000966;pmc PMC7081837;mid NIHMS1054911;pii 00002480-202001000-00008|
|30913104||1||MEDLINE||NLM||Curated||2020-09-14||2021-01-25||D000328 Adult;D005260 Female;D006333 Heart Failure;Q000276 immunology;MajorTopic Q000401 mortality;Q000628 therapy;D006353 Heart-Assist Devices;MajorTopic Q000009 adverse effects;D006801 Humans;D007249 Inflammation;Q000209 etiology;MajorTopic D008214 Lymphocytes;D008297 Male;D008875 Middle Aged;MajorTopic D009504 Neutrophils;D012189 Retrospective Studies;D013927 Thrombosis;MajorTopic Q000209 etiology;D016896 Treatment Outcome||IM||1538-943X||Electronic||ASAIO journal (American Society for Artificial Internal Organs : 1992)||ASAIO J||Internet||66;2||2020-02||United States||ASAIO J||9204109||1058-2916||Neutrophil to Lymphocyte Ratio Is Related to Thrombotic Complications and Survival in Continuous Flow Left Ventricular Assist Devices.||Ferrera Carlos From the Cardiovascular Institute, Hospital Clinico San Carlos, Madrid, Spain.;Department of Cardiology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom.;Gonzalez Fernandez Oscar Department of Cardiology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom.;Bouzas Noelia Department of Cardiology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom.;Castrodeza Javier Department of Cardiology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom.;Green Thomas Department of Cardiology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom.;Woods Andrew Department of Cardiothoracic Surgery, Freeman Hospital, Newcastle Upon Tyne, United Kingdom.;Robinson-Smith Nicola Department of Cardiothoracic Surgery, Freeman Hospital, Newcastle Upon Tyne, United Kingdom.;Tovey Sian Department of Cardiothoracic Surgery, Freeman Hospital, Newcastle Upon Tyne, United Kingdom.;Jakovljevic Djordje G Institutes of Genetic Medicine and Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.;Shah Asif Department of Cardiothoracic Surgery, Freeman Hospital, Newcastle Upon Tyne, United Kingdom.;Department of Cardiothoracic Transplantation, Freeman Hospital, Newcastle Upon Tyne, United Kingdom.;Booth Karen Department of Cardiothoracic Surgery, Freeman Hospital, Newcastle Upon Tyne, United Kingdom.;Department of Cardiothoracic Transplantation, Freeman Hospital, Newcastle Upon Tyne, United Kingdom.;Parry Gareth Department of Cardiothoracic Transplantation, Freeman Hospital, Newcastle Upon Tyne, United Kingdom.;Schueler Stephan Department of Cardiothoracic Surgery, Freeman Hospital, Newcastle Upon Tyne, United Kingdom.;Department of Cardiothoracic Transplantation, Freeman Hospital, Newcastle Upon Tyne, United Kingdom.;MacGowan Guy A Department of Cardiology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom.;Department of Cardiothoracic Transplantation, Freeman Hospital, Newcastle Upon Tyne, United Kingdom.;Institutes of Genetic Medicine and Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.||eng||Left ventricular assist devices (LVADs) have become an established treatment for advanced heart failure, although with long-term support these patients are potentially exposed to serious complications. Our purpose was to assess the role of the neutrophil to lymphocyte ratio (NLR) in LVAD complications and to evaluate if higher values of NLR after 4-6 months on LVAD support (NLR 4_6m) are associated with worse prognosis. All consecutive patients who received a HeartWare LVAD (N = 188, age 50 Â± 13 years), as bridge to transplant from December 2009 to January 2018 were included. Neutrophil to lymphocyte ratio was recorded pre-LVAD, post-LVAD, after 4-6 months on support and in case of a first adverse event to occur after the 4-6 months NLR was recorded. Median NLR values were pre-LVAD 4.26 (interquartile range [IQR], 3.1-6.9), at 1 day postoperative 11.6 (IQR, 8.3-16.6), and NLR 4_6m 4.4 (IQR, 3.0-6.4) (p < 0.001). Neutrophil to lymphocyte ratio increased significantly when patients had an infection, stroke, or pump thrombosis, as compared with the NLR 4_6m (all p < 0.05). Patients with NLR 4_6m â¥ median had higher rates of stroke and mortality. Survival time was shorter among patients with NLR 4_6m â¥ 4.4 (log-rank test p = 0.006). Neutrophil to lymphocyte ratio 4_6m was found to be predictive of increased mortality (area under the curve of 0.62, p = 0.007). After multivariate analysis, NLR 4_6m remained independently associated with increased mortality (hazard ratio [HR] 1.67; 95% confidence interval [CI], 1.03-2.7; p = 0.037). Neutrophil to lymphocyte ratio 4_6m values significantly increase in association with adverse events on LVAD support and are independently associated with mortality. This association suggests presence of inflammation adversely affects LVAD outcomes.||D016428 Journal Article||199-204||doi 10.1097/MAT.0000000000000971||pubmed 2019-3-27 6:0;medline 2020-9-15 6:0;entrez 2019-3-27 6:0||ppublish||pubmed 30913104;doi 10.1097/MAT.0000000000000971;pii 00002480-202002000-00014|
|30913105||1||MEDLINE||NLM||Automated||2020-02-06||2020-12-09||MajorTopic D000758 Anesthesia;MajorTopic D015199 Extracorporeal Membrane Oxygenation;D006801 Humans;MajorTopic D012128 Respiratory Distress Syndrome;D012189 Retrospective Studies||IM||RefType:CommentOn ASAIO J. 2018 Jul/Aug;64(4):544-551 29045280 ;RefType:CommentOn ASAIO J. 2019 May/Jun;65(4):e44-e45 30913098||1538-943X||Electronic||ASAIO journal (American Society for Artificial Internal Organs : 1992)||ASAIO J||Internet||65;4||United States||ASAIO J||9204109||1058-2916||Individualizing and Minimizing Sedation on Venovenous Extracorporeal Membrane Oxygenation in Acute Respiratory Distress Syndrome Patients, a Reply.||deBacker Julian Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, Department of Medicine and Interdepartmental Division of Critical Care Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada Department of Medicine and Interdepartmental Division of Critical Care Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada Department of Medicine and Interdepartmental Division of Critical Care Medicine, Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada.;Fan Eddy;Mehta Sangeeta||eng||D016422 Letter;D016420 Comment||e46||doi 10.1097/MAT.0000000000000970||pubmed 2019-3-27 6:0;medline 2020-2-7 6:0;entrez 2019-3-27 6:0||ppublish||pubmed 30913105;doi 10.1097/MAT.0000000000000970|
|30913107||1||MEDLINE||NLM||Curated||2020-09-14||2021-01-25||D000925 Anticoagulants;Q000627 therapeutic use;D000991 Antithrombins;Q000627 therapeutic use;D001777 Blood Coagulation;Q000187 drug effects;MajorTopic D001780 Blood Coagulation Tests;D015199 Extracorporeal Membrane Oxygenation;MajorTopic Q000009 adverse effects;D005260 Female;D006470 Hemorrhage;Q000209 etiology;Q000517 prevention & control;D006487 Hemostasis;D006801 Humans;D008297 Male;MajorTopic D013927 Thrombosis;Q000209 etiology;Q000517 prevention & control||0 D000925 Anticoagulants;0 D000991 Antithrombins||IM||1538-943X||Electronic||ASAIO journal (American Society for Artificial Internal Organs : 1992)||ASAIO J||Internet||66;2||2020-02||United States||ASAIO J||9204109||1058-2916||Monitoring Hemostasis During Extracorporeal Life Support.||Saifee Nabiha H From the Department of Laboratory Medicine, BloodWorks Northwest, Seattle, Washington.;Department of Laboratory Medicine, University of Washington, Seattle, Washington.;Brogan Thomas V Seattle Children's Hospital, Seattle, Washington.;Department of Pediatrics, University of Washington, Seattle, Washington.;McMullan David M Department of Laboratory Medicine, University of Washington, Seattle, Washington.;Division of Cardiothoracic Surgery, Department of Surgery, University of Washington, Seattle, Washington.;Yalon Larissa Seattle Children's Hospital, Seattle, Washington.;Matthews Dana C Seattle Children's Hospital, Seattle, Washington.;Division of Hematology and Oncology, Department of Pediatrics, University of Washington, Seattle, Washington.;Burke Christopher R Division of Cardiothoracic Surgery, Department of Surgery, University of Washington, Seattle, Washington.;Chandler Wayne L Department of Laboratory Medicine, University of Washington, Seattle, Washington.;Seattle Children's Hospital, Seattle, Washington.||eng||To balance the risk of bleeding versus circuit thrombosis during extracorporeal life support (ECLS), it is important to monitor anticoagulants and hemostasis. We evaluated the prothrombin time (PT), partial thromboplastin time (PTT), activated clotting time (ACT), and antifactor Xa heparin activity (aXa) correlation with changes in coagulation factor and heparin levels using in vitro and in vivo samples. aXa correlated with heparin (r = 0.97) and antithrombin (r = 0.98) but was unaffected by other parameters. PT correlated with coagulation factors (r = 0.88) but was minimally affected by heparin or other parameters. When single parameters were changed, ACT was insensitive to <0.5 U/ml heparin, correlated with coagulation factors (r = 0.99), and was affected by factor XII and platelets. When multiple parameters changed in vitro and in vivo, ACT was not correlated with heparin or coagulation factors. PTT correlated with heparin and coagulation factors individually but had low correlation when multiple parameters changed in vitro and in vivo. In conclusion, aXa is the most specific for heparin levels, and PT is most specific for coagulation factor levels making these assays well suited to monitor anticoagulation and hemostasis for patients on ECLS. PTT is highly variable when multiple parameters are changing in vitro and in vivo, but may be useful when aXa cannot be used because of interference. ACT is too insensitive to heparin, sensitive to too many other factors, and too imprecise to be useful for monitoring hemostasis during ECLS.||D016428 Journal Article||230-237||doi 10.1097/MAT.0000000000000993||pubmed 2019-3-27 6:0;medline 2020-9-15 6:0;entrez 2019-3-27 6:0||ppublish||pubmed 30913107;doi 10.1097/MAT.0000000000000993;pii 00002480-202002000-00019|
|30913108||1||MEDLINE||NLM||Automated||2019-10-29||2019-10-29||D003442 Crowns;D006801 Humans;MajorTopic D057873 Peri-Implantitis;D011446 Prospective Studies;D012189 Retrospective Studies;D012307 Risk Factors||1538-2982||Electronic||Implant dentistry||Implant Dent||Internet||28;2||2019-Apr||United States||Implant Dent||9206481||1056-6163||Periimplant Disease and Prosthetic Risk Indicators: A Literature Review.||Serino Giovanni Head of Department of Periodontology, Specialist in Periodontology, Specialist Clinics, Public Dental Service, SÃ¶dra Ãlvsborg Hospital, BorÃ¥s, Sweden.;Hultin Kristina Specialist in Prosthodontics, Department of Prosthodontics, Specialist Clinics, Public Dental Service, SÃ¶dra Ãlvsborg Hospital, BorÃ¥s, Sweden.||eng||PURPOSE OBJECTIVE The purpose of this review was to search in international published peer-review articles, data regarding prosthetic risk indicators affecting the incidence, prevalence, or treatment outcome of periimplant diseases.;MATERIALS AND METHODS METHODS A literature search was performed in MEDLINE via PubMed database of the US National Library of Medicine of articles published until February 2018; a manual search was also added. Randomized controlled trials, controlled trials, prospective and retrospective cohort studies with a minimum of 20 subjects, having cases with/without exposure to the risk indicator were included. Articles written in another language than English were not included.;RESULTS RESULTS The 17 articles reviewed indicated the cement residuals at abutments were identified as risk factors for both mucositis and periimplantitis. Among the screw-retained prosthetic reconstructions, prostheses screwed directly to the implants have higher risk to develop periimplant disease. The accessibility and the possibility to perform adequate plaque control around the prosthetic suprastructure decreases the risk for periimplant disease; convex emergence profiles seem to increase it. The crown margins located submucosa may impair the periimplant treatment outcome.;CONCLUSION CONCLUSIONS Prosthetic reconstruction on implants should be designed in a way to allow accessibility to proper plaque control. Screw-retained suprastructure and crown margins located supra-mucosa should be preferred when possible. When using cement-retained suprastructure, attention should be given to remove cement residuals.||D016428 Journal Article;D016454 Review||125-137||doi 10.1097/ID.0000000000000841||entrez 2019-3-27 6:0;pubmed 2019-3-27 6:0;medline 2019-10-30 6:0||ppublish||pubmed 30913108;doi 10.1097/ID.0000000000000841;pii 00008505-201904000-00006|
|30913109||1||MEDLINE||NLM||Curated||2019-10-29||2022-05-31||MajorTopic D015921 Dental Implants;D006801 Humans;MajorTopic D057873 Peri-Implantitis;MajorTopic D013280 Stomatitis||0 D015921 Dental Implants||1538-2982||Electronic||Implant dentistry||Implant Dent||Internet||28;2||2019-Apr||United States||Implant Dent||9206481||1056-6163||Soft-Tissue Conditions Around Dental Implants: A Literature Review.||Lin Guo-Hao Assistant Clinical Professor, Department of Orofacial Sciences, School of Dentistry, University of California San Francisco, San Francisco, CA.;Madi Iman M Private Practitioner, South County Periodontics & Implant Dentistry, Mission Viejo, CA.||eng||BACKGROUND BACKGROUND The aim of this article is to review the current understanding regarding periimplant soft-tissue conditions to minimize risk of periimplant mucositis and periimplantitis.;MATERIALS AND METHODS METHODS An electronic search was performed in 4 different databases. Articles were reviewed and summarized if the following criteria were met: published evidence with recommendations on soft-tissue conditions around dental implants.;RESULTS RESULTS An evaluation of various soft-tissue parameters, including the need of keratinized mucosa, periimplant mucosal height and phenotype, midfacial tissue level, and papillary fill, was performed based on the currently available evidence.;COMMENTS CONCLUSIONS The need of keratinized mucosa is the parameter investigated the most. A trend favors a need of a wide band of nonmobile keratinized mucosa is seen with the benefit of less incidence of periimplant mucositis. In addition, the influence of the mucosal height and tissue phenotype on periimplant tissue health remains inconclusive. Although other soft-tissue parameters, including papillary fill and midfacial tissue level, are not yet proven to be related to periimplantitis, they play a crucial role to achieve successful esthetics.;CONCLUSION CONCLUSIONS A limited amount of evidence was identified to correlate periimplant soft-tissue parameters with periimplantitis. However, a wide band of nonmobile keratinized mucosa, an adequate periimplant mucosal height, and a thick tissue phenotype might reduce the incidence of tissue inflammation and future complications.||D016428 Journal Article;D016454 Review||138-143||doi 10.1097/ID.0000000000000871||entrez 2019-3-27 6:0;pubmed 2019-3-27 6:0;medline 2019-10-30 6:0||ppublish||pubmed 30913109;doi 10.1097/ID.0000000000000871;pii 00008505-201904000-00007|
|30913110||1||MEDLINE||NLM||Automated||2019-10-29||2019-10-29||D006801 Humans;MajorTopic D052016 Mucositis;D009910 Oral Hygiene;MajorTopic D057873 Peri-Implantitis;D019736 Prostheses and Implants;MajorTopic D013280 Stomatitis||1538-2982||Electronic||Implant dentistry||Implant Dent||Internet||28;2||2019-Apr||United States||Implant Dent||9206481||1056-6163||Treatment Planning for Periimplant Mucositis and Periimplantitis.||Polyzois Ioannis Associate Professor\Consultant in Periodontology, Department of Restorative Dentistry and Periodontology, Dublin Dental University Hospital, Trinity College, Dublin, Ireland.||eng||PURPOSE OBJECTIVE A literature search was performed in a number of health care databases for articles published until January 2018.;DISCUSSION CONCLUSIONS A number of anatomical factors, risk indicators, possible aesthetic complications, and financial implications have to be taken into consideration before treatment commences. When diagnosed early, periimplant mucositis is a problem that can be easily managed as long as the patient is motivated and maintains good levels of oral hygiene. Periimplantitis is more difficult to treat and results can be unpredictable. Nonsurgical therapy has limited effectiveness on the treatment of periimplantitis, but it should always precede a surgical intervention. Clinically predictable surgical outcomes seem to rely mainly on the configuration of the bone defect, the position of the affected implant, and the patient's ability to perform good oral hygiene.;CONCLUSIONS CONCLUSIONS Thorough treatment planning of periimplant diseases is paramount for the success of the treatment that follows. Local and general factors as well as patients' expectations have to be considered before proceeding, but treatment planning should also allow for a degree of flexibility, which will accommodate the unknown parameters.||D016428 Journal Article||150-154||doi 10.1097/ID.0000000000000869||entrez 2019-3-27 6:0;pubmed 2019-3-27 6:0;medline 2019-10-30 6:0||ppublish||pubmed 30913110;doi 10.1097/ID.0000000000000869;pii 00008505-201904000-00009|
|30913111||1||MEDLINE||NLM||Automated||2019-10-29||2019-10-29||D000900 Anti-Bacterial Agents;MajorTopic D000890 Anti-Infective Agents;D003131 Combined Modality Therapy;D006801 Humans;MajorTopic D053685 Laser Therapy;MajorTopic D057873 Peri-Implantitis||0 D000900 Anti-Bacterial Agents;0 D000890 Anti-Infective Agents||1538-2982||Electronic||Implant dentistry||Implant Dent||Internet||28;2||2019-Apr||United States||Implant Dent||9206481||1056-6163||Nonsurgical Treatment of Periimplantitis.||Wang Chin-Wei Clinical Assistant Professor and Director of Predoctoral Periodontics, Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI.;Renvert Stefan Professor and Research Director, Oral Health Sciences, Kristianstad University School of Dentistry, Kristianstad, Sweden Visiting Professor, School of Dental Science, Trinity College, Dublin, Ireland.;Wang Hom-Lay Professor and Director of Graduate Periodontics, Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI.||eng||PURPOSE OBJECTIVE Periimplantitis has become an emerging challenge faced by practicing dentists worldwide. When treating periimplantitis, we should attempt to manage this problem via nonsurgical therapies that include addressing all modifiable systemic risk factors and local contributing factors. Hence, the aim of this narrative review was to examine published studies on nonsurgical treatment of periimplantitis and evaluate their effectiveness and limitations.;MATERIALS AND METHODS METHODS A literature search was performed in MEDLINE via PubMed database up to December 31, 2017. Current published clinical approaches focused on mechanical debridement, adjunctive antiseptic therapy, adjunctive antibiotic therapy, laser-assisted therapy, and combination approaches were included in this analysis.;RESULTS RESULTS Nonsurgical therapy of periimplantitis may result in complete healing of the disease and the patient is then placed on a supportive maintenance program. If the disease is not resolved and surgical intervention is not an option, active nonsurgical retreatment may be considered. In many cases where disease is not resolved, surgical therapy or implant removal could be considered.;CONCLUSIONS CONCLUSIONS Nonsurgical treatment of periimplantitis usually provides clinical improvements in reducing bleeding tendency and in some cases pocket reduction. Early diagnosis, detection, and intervention remain the key for managing periimplantitis.||D016428 Journal Article;D016454 Review||155-160||doi 10.1097/ID.0000000000000846||entrez 2019-3-27 6:0;pubmed 2019-3-27 6:0;medline 2019-10-30 6:0||ppublish||pubmed 30913111;doi 10.1097/ID.0000000000000846;pii 00008505-201904000-00010|
|30913112||1||MEDLINE||NLM||2020-04-15||2020-07-01||D000328 Adult;D000368 Aged;D001170 Arthritis, Infectious;MajorTopic Q000150 complications;D019643 Arthroplasty, Replacement;MajorTopic Q000009 adverse effects;D015331 Cohort Studies;D005260 Female;D006801 Humans;D007595 Joint Prosthesis;MajorTopic Q000009 adverse effects;D053208 Kaplan-Meier Estimate;D008297 Male;D008875 Middle Aged;D016016 Proportional Hazards Models;D016459 Prosthesis-Related Infections;MajorTopic Q000209 etiology;D012189 Retrospective Studies;D012307 Risk Factors||IM||RefType:CommentIn Clin Orthop Relat Res. 2019 Jul;477(7):1613-1614 31107320||1528-1132||Electronic||Clinical orthopaedics and related research||Clin Orthop Relat Res||Internet||477;7||2019-07||United States||Clin Orthop Relat Res||75674||0009-921X||Patients with a History of Treated Septic Arthritis are at High Risk of Periprosthetic Joint Infection after Total Joint Arthroplasty.||Sultan Assem A A. A. Sultan, B. Mahmood, L. T. Samuel, J. George, M. Faour, A. K. Klika, Department of Orthopaedic Surgery, Cleveland Clinic, Cleveland, Ohio, USA C. E. Pelt, M. B. Anderson, Department of Orthopaedic Surgery, Utah University Medical Center, Salt Lake City, UT, USA C. A. Higuera, Department of Orthopaedic Surgery, Cleveland Clinic, Weston, FL, USA.;Mahmood Bilal;Samuel Linsen T;George Jaiben;Faour Mhamad;Pelt Christopher E;Anderson Mike B;Klika Alison K;Higuera Carlos A||eng||BACKGROUND In patients undergoing total joint arthroplasty (TJA), increasing attention has been directed recently toward identifying specific patient-related risk factors that may predispose patients to periprosthetic joint infection (PJI). Currently, it is unclear whether having a history of a treated native septic arthritis is a risk factor for PJI after TJA in the same joint. Previous studies have reported contradictory evidence and results varied between a substantially higher rates of PJIs to very low or no reported PJIs.;QUESTIONS/PURPOSES (1) What is the risk of PJI in patients who received TJA and had a history of treated same-joint native joint septic arthritis and (2) What are the associated risk factors for these patients developing PJI?;METHODS This was a multicenter retrospective analysis of patients who received primary THA or TKA between January 2000 and December 2016 and who had a history of treated native joint septic arthritis in the same joint. Patients were included in the study only if they were considered to have resolved their joint infection based on a preoperative evaluation that included: (1) the absence of clinical symptoms and signs of active infection or local joint inflammation, (2) recent plain radiographs showing only advanced degenerative changes without evidence of active osteolysis or bone infection, (3) preoperative laboratory investigations for infection, including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and total leukocyte counts within normal ranges. Patients were reviewed for the occurrence of postoperative PJI. The final cohort included 62 patients who had a mean followup of 4.4 years (range, 3 months-17 years) from the time of TJA. A total of 21 patients (34%) had less than 2 years of followup, including six (10%) mortalities. In total, eight patients (13%) died during the study period, none of which were due to PJI. Patient characteristics, time interval from treatment of septic arthritis to TJA, and Charlson comorbidity index adjusted for age were collected. We used a Kaplan-Meier analysis to estimate the overall survivorship among all TJAs as well as those who underwent THA versus TKA, and we performed a statistical comparison using the Mantel-Cox log-rank test. We performed a Cox regression hazard ratio (HR) survival analysis to identify risk factors for PJI. The PJI odds ratios (OR) for patients who underwent TJA within 2 years of septic arthritis were calculated as an additional temporal analysis.;RESULTS In patients with a history of treated same-joint native septic arthritis, the proportion of PJI was five of 62 patients (8%). The Kaplan-Meier analysis demonstrated an overall survivorship free from PJI of 92% at 14.5 Â± 1.14 years (95% confidence interval [CI] = 12.3-16.8 years). All PJI cases occurred only in patients who underwent TKA, which when analyzed separately, yielded a survivorship of 85% at 10.5 Â± 0.9 years (95% CI = 8.7-12.3 years) versus 100% in patients who underwent THA (p = 0.068). Mean time to PJI occurrence was 10 months (range, 2-20 months). After controlling for relevant confounding variables, such as age, sex, affected joint and comorbidities, we found smoking (HR, 8.06; 95% CI, 1.33-48.67; p = 0.023) to be associated with increased risk for PJI development.;CONCLUSION Patients with history of native joint infections are at higher risk of PJI, especially smokers. Despite our limitations, this study suggests careful assessment of several other factors in these patients, including allowing a minimum interval of 2 years from the time of resolving native joint septic arthritis to TJA. Patients who are undergoing TKA seem to be more prone to the PJI risk and may benefit from more aggressive planning. In addition, medical optimization of comorbidities that may confer additional risk, such as diabetes, become exceptionally important in these patients.;LEVEL OF EVIDENCE Level III, therapeutic study.||D016428 Journal Article;D016448 Multicenter Study||1605-1612||doi 10.1097/CORR.0000000000000688||pubmed 2019-3-27 6:0;medline 2020-4-16 6:0;entrez 2019-3-27 6:0||ppublish||pubmed 30913112;doi 10.1097/CORR.0000000000000688;pmc PMC6999997|